Advertisement

Advertisement

News

SABCS 2024: Margetuximab vs Trastuzumab Combinations in Early HER2-Positive Breast Cancer

Medical Literature

Unresectable, Primary NSCLC: Is SBRT of Benefit in Combination With Conventional Therapy?

News

Combination of Sintilimab and Nab-Paclitaxel in Advanced Squamous NSCLC

News

SABCS 2024: Correlation of Biomarkers With Outcomes in Early Triple-Negative Breast Cancer

News

Relapse Patterns From Long-Term Subgroup Analysis of IMpower010

News

Using Machine Learning Model to Predict NSCLC Progression After Upfront Pembrolizumab

News

ASTRO 2024: French Trial of Radiotherapy Plus T-DXd in HER2-Positive Breast Cancer

Nicolas Guibert, MD, PhD, on Non–Small Cell Lung Cancer: Clinical Implications of Using a New Algorithm to Predict Response to Immunotherapy

Hope Rugo, MD, on Clinical Implications of New Findings on the Benefits of Sacituzumab Govitecan-hziy in Advanced Breast Cancer

View More

Advertisement

JNCCN Spotlights

(UPDATE) Pertuzumab (Breast Cancer)

View More

More

News

Immune Biomarkers as Predictors of Survival and Risk in Patients With Melanoma

SITC 2024: Elucidating the Therapeutically Relevant Mechanisms of TROP2 in Breast Cancer

SITC 2024: Potential Biomarker of Disease Progression After Immunotherapy for Advanced Melanoma

Neurologic Symptoms and Immunotherapy for Melanoma Brain Metastases: A View From New Zealand

SITC 2024: CRISPR Editing Yields New B-Cell Strategies for Treating HER2-Positive Breast Cancer

SABCS 2024: Margetuximab vs Trastuzumab Combinations in Early HER2-Positive Breast Cancer

Investigating Immunotherapy Resistance in Merkel Cell Carcinoma

New Bispecific Antibody Granted Approval in NSCLC Harboring <em>NRG1</em> Gene Fusion

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Case Series: Defining the Role of Immunotherapy Across Melanoma Care

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Minimizing the Impact of imAEs and Maximizing Efficacy of ICIs: AEs Affecting the Skin

View More

Available

Clinical Trials

A Study to Learn About the Effects of the Combination of Elranatamab

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2024 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.